Global Cell Counting Market worth $19.27 billion by 2030

The report" Global Cell Counting" Market by Product (Instruments - Spectrophotometers, Flow Cytometers, Haematology Analyzers, Cell Counters; Consumables & Accessories - Reagents, Microplates, Others), End-user (Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others) and Regional (North America, Europe, APAC, Latin America, The Middle East & Africa)- Global Forecast to 2030. "In 2020, the Global Cell Counting Market share was USD 9.8 billion. It is predicted to reach USD 19.27 billion by 2030, with a CAGR of 7 % throughout the forecasted period.

To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/cell-counting-market

KEY FACTORS AUGMENTING THE MARKET GROWTH

The rising incidence of chronic illnesses and rising technical advancements and product releases in the cell counting market globally are likely to propel the industry forward.

By Product, the 'Spectrophotometer segment holds the most significant market share.

Spectrophotometers showed sheer market dominance. As a result, spectrophotometry has evolved as the primary method for quantifying cell concentration in research, medicine, and bioprocessing. The ability of these sensors to precisely monitor a wide range of light intensities has led to their growing acceptance. However, the instrument's high price is predicted to slow the market acceptance rate in the future.

By End-users, the "Hospital & Diagnostic Laboratory" segment holds the maximum share of the market.

Based on end-users, hospitals and diagnostic laboratories would develop at the quickest CAGR during the predicted period. A boost in board approval for cell culture-based antibiotics, increasing pharmaceutical R&D investment, and commercial development by various pharmaceutical corporations contribute to this category's rapid expansion. Furthermore, the highly advanced infrastructure facilities equipped with new technology make many AIDS, and cancer patients rely on hospitals and diagnostic laboratories for appropriate treatment and evaluation.

By Region, North America comprehensively led the market in terms of revenue.

Based on region, because of the increased frequency of chronic diseases such as heart and blood problems, North America dominated the cell counting devices industry. In addition, improved healthcare infrastructure and the expansion of government-sponsored stem cell research and development activities will boost the cell counting devices market ahead in this region. 

On the other hand, the cell counting devices market is predicted to increase in the Asia Pacific due to various clinical research and biopharmaceutical enterprises.

SOME OF THE CRUCIAL EXISTING MARKET PLAYERS:

Below mentioned players are the ones who are the market leaders of Global Cell Counting - Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer Inc, Olympus Corporation, HORIBA Ltd, Logos Biosystems Inc, Corning Incorporated, Tecan Trading AG, Abbott, General Electric Company, Boule Diagnostics AB, Becton, Dickinson and Company, Tip Biosystems, Agilent Technologies Inc, Sysmex Corporation, Siemens Healthcare Private Limited, Diconex, Beckman Coulter Inc, Nexcelom Bioscience LLC, ChemoMetec A/S, Bio-Rad Laboratories Inc, Advanced Instruments, R&D Systems, Inc. Cole-Parmer Instrument Company LLC

Recent Developments: -

• On 14th March 2022, the new BC-700 Series was successfully launched by Mindray, which is a ground-breaking haematology analyzer series that includes both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) assays.
• On 2nd February 2022, for its Guava range of Flow Cytometry Instruments and Reagents, Abacus dx collaborated with Luminex on a new agreement. This initiative is likely to drive market growth efficiently in the future.
• In June 2021, CytoSMART Technologies created one of the first fluorescent cell counters. The CytoSMART Exact FL is a highly autonomous dual fluorescence cell counter with artificial intelligence (AI) algorithms that provide highly reliable picture recognition.
• On 31st March 2020, Danaher corporation completed the acquisition of the biopharma business of GE and named it Cytiva, which operates as a standalone company within the life science section of Danahar.

The report" Global Cell Counting" Market by Product (Instruments - Spectrophotometers, Flow Cytometers, Haematology Analyzers, Cell Counters; Consumables & Accessories - Reagents, Microplates, Others), End-user (Hospitals & Diagnostic Laboratories, Research & Academic Institutes, Pharmaceutical & Biotechnology Companies, Others) and Regional (North America, Europe, APAC, Latin America, The Middle East & Africa)- Global Forecast to 2030. "In 2020, the Global Cell Counting Market share was USD 9.8 billion. It is predicted to reach USD 19.27 billion by 2030, with a CAGR of 7 % throughout the forecasted period.

To know more about the report, Click on the link :- https://www.strategicmarketresearch.com/market-report/cell-counting-market

KEY FACTORS AUGMENTING THE MARKET GROWTH

The rising incidence of chronic illnesses and rising technical advancements and product releases in the cell counting market globally are likely to propel the industry forward.

By Product, the 'Spectrophotometer segment holds the most significant market share.

Spectrophotometers showed sheer market dominance. As a result, spectrophotometry has evolved as the primary method for quantifying cell concentration in research, medicine, and bioprocessing. The ability of these sensors to precisely monitor a wide range of light intensities has led to their growing acceptance. However, the instrument's high price is predicted to slow the market acceptance rate in the future.

By End-users, the "Hospital & Diagnostic Laboratory" segment holds the maximum share of the market.

Based on end-users, hospitals and diagnostic laboratories would develop at the quickest CAGR during the predicted period. A boost in board approval for cell culture-based antibiotics, increasing pharmaceutical R&D investment, and commercial development by various pharmaceutical corporations contribute to this category's rapid expansion. Furthermore, the highly advanced infrastructure facilities equipped with new technology make many AIDS, and cancer patients rely on hospitals and diagnostic laboratories for appropriate treatment and evaluation.

By Region, North America comprehensively led the market in terms of revenue.

Based on region, because of the increased frequency of chronic diseases such as heart and blood problems, North America dominated the cell counting devices industry. In addition, improved healthcare infrastructure and the expansion of government-sponsored stem cell research and development activities will boost the cell counting devices market ahead in this region. 

On the other hand, the cell counting devices market is predicted to increase in the Asia Pacific due to various clinical research and biopharmaceutical enterprises.

SOME OF THE CRUCIAL EXISTING MARKET PLAYERS:

Below mentioned players are the ones who are the market leaders of Global Cell Counting - Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer Inc, Olympus Corporation, HORIBA Ltd, Logos Biosystems Inc, Corning Incorporated, Tecan Trading AG, Abbott, General Electric Company, Boule Diagnostics AB, Becton, Dickinson and Company, Tip Biosystems, Agilent Technologies Inc, Sysmex Corporation, Siemens Healthcare Private Limited, Diconex, Beckman Coulter Inc, Nexcelom Bioscience LLC, ChemoMetec A/S, Bio-Rad Laboratories Inc, Advanced Instruments, R&D Systems, Inc. Cole-Parmer Instrument Company LLC

Recent Developments: -

• On 14th March 2022, the new BC-700 Series was successfully launched by Mindray, which is a ground-breaking haematology analyzer series that includes both complete blood count (CBC) and erythrocyte sedimentation rate (ESR) assays.
• On 2nd February 2022, for its Guava range of Flow Cytometry Instruments and Reagents, Abacus dx collaborated with Luminex on a new agreement. This initiative is likely to drive market growth efficiently in the future.
• In June 2021, CytoSMART Technologies created one of the first fluorescent cell counters. The CytoSMART Exact FL is a highly autonomous dual fluorescence cell counter with artificial intelligence (AI) algorithms that provide highly reliable picture recognition.
• On 31st March 2020, Danaher corporation completed the acquisition of the biopharma business of GE and named it Cytiva, which operates as a standalone company within the life science section of Danahar.